FDA Declines Guidance on Foreign Drug Imports Amid Regulatory Concerns
The FDA has declined to issue specific guidance on the importation of foreign drugs by alternative funding programs (AFPs), despite concerns about the legality and safety of these practices. AFPs connect patients with affordable versions of expensive medications from foreign markets, potentially violating U.S. import laws. The FDA acknowledged the risks of contaminated or counterfeit drugs but stated that issuing guidance is not warranted at this time. The decision leaves a regulatory grey area, impacting patient advocacy groups seeking clarity on the legality of AFP practices. 
